Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China
IntroductionThis retrospective study aims to present the characteristics of Posner-Schlossman syndrome (PSS) relapse following inactivated COVID-19 vaccination.MethodsFrom 2020 to 2022, 12 out of 106 PSS patients undergoing relapses after any dose of inactivated COVID-19 vaccines were enrolled. Medi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2022.1051378/full |
| _version_ | 1797953939708051456 |
|---|---|
| author | Qilian Sheng Qilian Sheng Qilian Sheng Qilian Sheng Yanan Sun Yanan Sun Yanan Sun Yanan Sun Ruyi Zhai Ruyi Zhai Ruyi Zhai Ruyi Zhai Xintong Fan Xintong Fan Xintong Fan Xintong Fan Yue Ying Yue Ying Yue Ying Yue Ying Xiangmei Kong Xiangmei Kong Xiangmei Kong Xiangmei Kong |
| author_facet | Qilian Sheng Qilian Sheng Qilian Sheng Qilian Sheng Yanan Sun Yanan Sun Yanan Sun Yanan Sun Ruyi Zhai Ruyi Zhai Ruyi Zhai Ruyi Zhai Xintong Fan Xintong Fan Xintong Fan Xintong Fan Yue Ying Yue Ying Yue Ying Yue Ying Xiangmei Kong Xiangmei Kong Xiangmei Kong Xiangmei Kong |
| author_sort | Qilian Sheng |
| collection | DOAJ |
| description | IntroductionThis retrospective study aims to present the characteristics of Posner-Schlossman syndrome (PSS) relapse following inactivated COVID-19 vaccination.MethodsFrom 2020 to 2022, 12 out of 106 PSS patients undergoing relapses after any dose of inactivated COVID-19 vaccines were enrolled. Medical histories, information on the vaccination and systemic adverse events were collected. Patients were treated with corticosteroids, intraocular pressure (IOP)-lowering drugs and systemic immunosuppressive agents (if needed). Daily regimen and release course were noted.ResultsThe recurrence rate after vaccination was 11.32% (12/106, 95% CI: 5.29%–17.35%) among 106 PSS patients we surveyed. All the 12 patients were inoculated with inactivated COVID-19 vaccines developed by Sinopharm, China. The mean time of relapse was 5.27 ± 3.72 days (range: 1–13 days, median: 4 days). Higher IOP and more keratic precipitates (KPs) were seen in the relapse following vaccination (33.55 ± 12.99 mmHg, 91.67% had KPs compared to 25.38 ± 3.80 mmHg, 33.33% had KPs in previous relapse, P = 0.009). The mean release course was 30.71 ± 34.74 days for the relapse following vaccination and 7.33 ± 6.51 days for previous relapses. The attack frequency before and after vaccination was 3.56 ± 2.07 and 9.11 ± 7.34 times per year (P = 0.044). Higher daily doses of corticosteroids, IOP-lowering drugs and ganciclovir were needed to maintain stable course, though the difference did not reach statistical significance.DiscussionMore frequent relapses and harder control of IOP were found in PSS relapse following COVID-19 vaccination. Ophthalmologists need to be aware of the group vulnerability and take precautions, though the pathogenesis is still under investigation. |
| first_indexed | 2024-04-10T23:09:51Z |
| format | Article |
| id | doaj.art-3d2583a9640446e4aaf00e57b0c5d694 |
| institution | Directory Open Access Journal |
| issn | 2296-2565 |
| language | English |
| last_indexed | 2024-04-10T23:09:51Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj.art-3d2583a9640446e4aaf00e57b0c5d6942023-01-13T06:04:38ZengFrontiers Media S.A.Frontiers in Public Health2296-25652023-01-011010.3389/fpubh.2022.10513781051378Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in ChinaQilian Sheng0Qilian Sheng1Qilian Sheng2Qilian Sheng3Yanan Sun4Yanan Sun5Yanan Sun6Yanan Sun7Ruyi Zhai8Ruyi Zhai9Ruyi Zhai10Ruyi Zhai11Xintong Fan12Xintong Fan13Xintong Fan14Xintong Fan15Yue Ying16Yue Ying17Yue Ying18Yue Ying19Xiangmei Kong20Xiangmei Kong21Xiangmei Kong22Xiangmei Kong23Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, ChinaNational Health Commission Key Laboratory of Myopia (Fudan University), Shanghai, ChinaKey Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, ChinaShanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, ChinaEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, ChinaNational Health Commission Key Laboratory of Myopia (Fudan University), Shanghai, ChinaKey Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, ChinaShanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, ChinaEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, ChinaNational Health Commission Key Laboratory of Myopia (Fudan University), Shanghai, ChinaKey Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, ChinaShanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, ChinaEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, ChinaNational Health Commission Key Laboratory of Myopia (Fudan University), Shanghai, ChinaKey Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, ChinaShanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, ChinaEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, ChinaNational Health Commission Key Laboratory of Myopia (Fudan University), Shanghai, ChinaKey Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, ChinaShanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, ChinaEye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, ChinaNational Health Commission Key Laboratory of Myopia (Fudan University), Shanghai, ChinaKey Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, ChinaShanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, ChinaIntroductionThis retrospective study aims to present the characteristics of Posner-Schlossman syndrome (PSS) relapse following inactivated COVID-19 vaccination.MethodsFrom 2020 to 2022, 12 out of 106 PSS patients undergoing relapses after any dose of inactivated COVID-19 vaccines were enrolled. Medical histories, information on the vaccination and systemic adverse events were collected. Patients were treated with corticosteroids, intraocular pressure (IOP)-lowering drugs and systemic immunosuppressive agents (if needed). Daily regimen and release course were noted.ResultsThe recurrence rate after vaccination was 11.32% (12/106, 95% CI: 5.29%–17.35%) among 106 PSS patients we surveyed. All the 12 patients were inoculated with inactivated COVID-19 vaccines developed by Sinopharm, China. The mean time of relapse was 5.27 ± 3.72 days (range: 1–13 days, median: 4 days). Higher IOP and more keratic precipitates (KPs) were seen in the relapse following vaccination (33.55 ± 12.99 mmHg, 91.67% had KPs compared to 25.38 ± 3.80 mmHg, 33.33% had KPs in previous relapse, P = 0.009). The mean release course was 30.71 ± 34.74 days for the relapse following vaccination and 7.33 ± 6.51 days for previous relapses. The attack frequency before and after vaccination was 3.56 ± 2.07 and 9.11 ± 7.34 times per year (P = 0.044). Higher daily doses of corticosteroids, IOP-lowering drugs and ganciclovir were needed to maintain stable course, though the difference did not reach statistical significance.DiscussionMore frequent relapses and harder control of IOP were found in PSS relapse following COVID-19 vaccination. Ophthalmologists need to be aware of the group vulnerability and take precautions, though the pathogenesis is still under investigation.https://www.frontiersin.org/articles/10.3389/fpubh.2022.1051378/fullPosner-Schlossman syndromeCOVID-19vaccineinactivateduveitis |
| spellingShingle | Qilian Sheng Qilian Sheng Qilian Sheng Qilian Sheng Yanan Sun Yanan Sun Yanan Sun Yanan Sun Ruyi Zhai Ruyi Zhai Ruyi Zhai Ruyi Zhai Xintong Fan Xintong Fan Xintong Fan Xintong Fan Yue Ying Yue Ying Yue Ying Yue Ying Xiangmei Kong Xiangmei Kong Xiangmei Kong Xiangmei Kong Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China Frontiers in Public Health Posner-Schlossman syndrome COVID-19 vaccine inactivated uveitis |
| title | Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China |
| title_full | Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China |
| title_fullStr | Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China |
| title_full_unstemmed | Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China |
| title_short | Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China |
| title_sort | posner schlossman syndrome relapse following inactivated covid 19 vaccination in china |
| topic | Posner-Schlossman syndrome COVID-19 vaccine inactivated uveitis |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2022.1051378/full |
| work_keys_str_mv | AT qiliansheng posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT qiliansheng posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT qiliansheng posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT qiliansheng posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT yanansun posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT yanansun posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT yanansun posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT yanansun posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT ruyizhai posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT ruyizhai posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT ruyizhai posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT ruyizhai posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT xintongfan posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT xintongfan posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT xintongfan posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT xintongfan posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT yueying posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT yueying posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT yueying posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT yueying posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT xiangmeikong posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT xiangmeikong posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT xiangmeikong posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina AT xiangmeikong posnerschlossmansyndromerelapsefollowinginactivatedcovid19vaccinationinchina |